Pharma Mar SAU (LON:0RC6) recently reported financial results for 2017. Sales for the year were down 0.9% to €162.6m compared to 2016. Yondelis sales fell 4.1% to €84.6m, mainly due to pricing erosion in Europe. However, the consumer chemicals division continues to grow and was up 3.4% for the year to €72.0m. Importantly, the company’s Phase III trial testing Zepsyre® in small cell lung cancer (SCLC) patients is around 75% enrolled and expected to be fully enrolled in the middle of this year with data in H119.
ATLANTIS trial in SCLC patients progressing nicely
PharmaMar announced that the 600-patient ATLANTIS trial of Zepsyre in relapsed SCLC patients is around 75% enrolled, with enrolment expected to complete in June/July. With this timing in mind, top-line data are expected around H119. As a reminder, in previous data at the same dose being used in ATLANTIS, Zepsyre demonstrated PFS of 5.3 months, which is higher than the three to four months typically seen with Topotecan, the current standard of care.
To read the entire report Please click on the pdf File Below: